FDA Approves First Biosimilar Drug

This spring the Food and Drug Administration approved the first biosimilar drug for use in the United States, opening the regulatory door to lower-cost versions of a class of pharmaceuticals called biologics. The drug, Zarzio, helps patients receiving chemotherapy make white blood cells, preventing infections common among cancer patients. It is considered therapeutically equivalent to the existing biologic, Neupogen.  

So why is this important? READ MOREneupogen-16148_3

2015 CRC – BCRF Patient Meeting

In honor of Miles Pendleton, a CLL patient and advocate, the CLL Research Consortium and the Blood Cancer Research Fund, hosted a patient education and empowerment meeting.  The meeting took place at UC San Diego Moores Cancer Center, in La Jolla, California.  We will covered a wide-range of topics: from early stage CLL, prognosis, targeted therapies, to forming your own CLL team. By the end of the meeting the participants had a clear understanding of the new research developments, treatments types, and how to address needs beyond just treatment of CLL. 

CRC2015 Panel

We are now in the process of posting videos of each of our wonderful speakers!  Keep coming back to this page for the complete listing of speakers! Click on the name of the speaker and you’ll be taken to the YouTube posting!

Cirmtuzumab: Here About the Promising New Therapy

Researchers at UC San Diego are developing a new drug to treat CLL. The drug, cirmutuzumab, is an antibody designed to attach to a protein on the surface of CLL cells. Researchers hope that this process will block cancerous cell growth and survival. Right now, cirmtuzumab is being tested for its safety and effectiveness in humans in a Phase One clinical trial.  “A brand new way to target and kill blood cancer,” WNDU, features Thomas Kipps, MD, PhD.
(Source: http://www.utsandiego.com/news/2014/sep/17/ucsd-leukemia-cll-trial-kipps-cirm/, https://clinicaltrials.gov/ct2/show/NCT02222688?term=cirmtuzumab&rank=1 )

And see: http://medicalxpress.com/news/2014-10-first-in-human-trials-therapeutic-stem-cell.html

Wtumblr_nl44wnTdjK1qievavo1_500AAY

 

The Role of a NOTCH1 Mutation for CLL Patients

The Promise of Immuno-Oncology to Treat CLL

From Patient Power:

Could a patient’s own immune system be sparked to fight chronic lymphocytic leukemia (CLL)? Research into immunotherapy—or immuno-oncology—CLL treatment approaches is currently underway and creating buzz. Dr. Thomas Kipps, a leading CLL expert, explores immuno-oncology treatments in development, how they work and why he finds the research “truly exciting.”

http://www.patientpower.info/video/ash-coverage-the-promise-of-immuno-oncology-to-treat-cll

CLL Patient Meeting April 23rd, 2015!!!!

In honor of Miles Pendleton, CLL patient and advocate, the CLL Research Consortium, (along with the Blood Cancer Research Fund), is hosting a patient education and empowerment meeting. The meeting will take place at UC San Diego Moores Cancer Center, in La Jolla, California. We will cover a wide-range of topics: from early stage CLL, prognosis, targeted therapies, to forming your own CLL team. By the end of the meeting the participants will have a clear understanding of the new research developments, treatments types, and how to address needs beyond just treatment of CLL. Participants will also understand the importance of clinical research and how clinical research benefits everyone! For ticket or additional information go to:

https://crcpatientmeeting2015.eventbrite.com

Panel

Frontline Cancer: Retraining your immune system to fight cancer

Given the complexities of cancer, there is not – and likely never will be – a single way to destroy it. Instead, the oncologist’s armamentarium must be stocked with many weapons, which include diverse advances in chemotherapy, radiation, surgery and stem cell technologies.  For the full story CLICK HERE!

Scott-Lippman-Column-Photo-2013-FI_t180

Dr. Scott Lippman, Director of the UC San Diego Moores Cancer Center

Anti-leukemia drug may also work against ovarian cancer

An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well, reported researchers at the University of California, San Diego School of Medicine and the Blood Cancer Research Fund, in a study published in the Nov. 17 online early edition of the Proceedings of the National Academy of Sciences (PNAS).    http://tinyurl.com/op7g28k